Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
74.58(c) 73.94(c) 74.8(c) 77.58(c) 75.68(c) Last
490 645 597 295 690 363 1 807 951 1 084 573 Volume
+0.13% -0.86% +1.16% +3.72% -2.45% Change
More quotes
Financials (USD)
Sales 2020 20 056 M
EBIT 2020 2 674 M
Net income 2020 1 427 M
Debt 2020 10 931 M
Yield 2020 1,52%
Sales 2021 21 486 M
EBIT 2021 3 029 M
Net income 2021 1 676 M
Debt 2021 10 183 M
Yield 2021 1,78%
P/E ratio 2020 17,1x
P/E ratio 2021 14,4x
EV / Sales2020 1,77x
EV / Sales2021 1,61x
Capitalization 24 472 M
More Financials
Company
Fresenius Medical Care is the world's leading supplier of services and equipment for patients with kidney problems. Net sales break down by activity as follows: - clinical care services (80.2%): operated, at the end of 2018, 3,928 institutions; - manufacturing of dialyzers and related products... 
More about the company
Surperformance© ratings of Fresenius Medical Care AG
Trading Rating : Investor Rating :
More Ratings
Latest news on FRESENIUS MEDICAL CARE AG
02/21FRESENIUS MEDICAL CARE : published form 20-F for the fiscal year 2019
PU
02/21FRESENIUS MEDICAL CARE : published form 20-F for the fiscal year 2019
EQ
02/20FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 50 of the Wp..
EQ
02/20Fresenius forecasts 2020 profit growth driven by drug, dialysis units
RE
02/20Fresenius 4Q Net Profit Flat; Creates JV With Vifor in China
DJ
02/19FRESENIUS MEDICAL CARE : says fourth-quarter operating profit up 3%
RE
02/19FRESENIUS MEDICAL CARE : COMPLETE OVERVIEW OF THE RESULTS FOR THE FOURTH QUARTER..
PU
02/19FRESENIUS MEDICAL CARE : achieves 2019 guidance and confirms 2020 outlook of sus..
EQ
02/19FRESENIUS : Subsidiary to Acquire Hospital in Bogota
DJ
02/17FRESENIUS MEDICAL CARE AG & CO. KGAA : annual earnings release
02/17FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
02/10FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
02/03FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
01/27FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
01/20FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
More news
News in other languages on FRESENIUS MEDICAL CARE AG
02/21FRESENIUS MEDICAL CARE : veröffentlicht Form 20-F für das Geschäftsjahr 2019
02/21Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2019
02/20FRESENIUS MEDICAL CARE AG & CO. KGAA : Veröffentlichung gemäß § 50 WpHG mit dem ..
02/20La Bourse de Francfort en baisse, vigilante sur le coronavirus (Dax:-0,91%)
02/20Aktien Frankfurt Schluss: Dax auf Tagestief
More news
Analyst Recommendations on FRESENIUS MEDICAL CARE AG
More recommendations
Sector news : Healthcare Facilities & Services - NEC
02/20Fresenius forecasts 2020 profit growth driven by drug, dialysis units
RE
02/20Fresenius 4Q Net Profit Flat; Creates JV With Vifor in China
DJ
02/19FRESENIUS MEDICAL CARE : says fourth-quarter operating profit up 3%
RE
02/19FRESENIUS : Subsidiary to Acquire Hospital in Bogota
DJ
02/14Canada Seeks Talks to End Rail Blockades -- Update
DJ
More sector news : Healthcare Facilities & Services - NEC
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 86,56  $
Last Close Price 82,09  $
Spread / Highest target 31,5%
Spread / Average Target 5,44%
Spread / Lowest Target -40,7%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer